Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
- Conditions
- Social Phobia
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-02-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 185
- Registration Number
- NCT00191022
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, West Allis, Wisconsin, United States
Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence
- Conditions
- Urinary Incontinence, Stress
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2765
- Registration Number
- NCT00190996
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Surrey, United Kingdom
Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.
- Conditions
- Non-Small-Cell Lung Carcinoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 64
- Registration Number
- NCT00191620
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/ GMT - 5 hours, EST), or speak with your personal physician, Mexico City, Mexico
A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma
- Conditions
- Mesothelioma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT00190762
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9:00 AM - 5:00 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician, Ottawa, Ontario, Canada
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
- Conditions
- Breast Neoplasms
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00191672
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katy, Texas, United States
Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine Trials
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT00191594
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zamora, Spain
Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence
- Conditions
- Urinary Stress Incontinence
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00190567
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Indianapolis, Indiana, United States
Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma
- Conditions
- Gastrointestinal Neoplasms
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00190801
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of
Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania
- Conditions
- Bipolar Disorder
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00190892
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St. Petersburg, Russian Federation
A Study of LY317615 in Patients With Brain Tumors
- Conditions
- Malignant Glioma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00190723
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bethesda, Maryland, United States